stockrow
Friday 6 November 2026
Export INCR’s income statement to Excel — free account
InterCure Ltd.
INCR Healthcare Drug Manufacturers Specialty & Generic
InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $78.5 million, up 18.4% from fiscal 2024.
3.36
0.06
+1.82%
Follow INCR
Alert me
| Older periods | Mar '23 | Jun '23 | Jun '24 | Jun '25 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | — | — | — |
| 6.15% | 3.98% | 0.00% | 0.00% | ||
| 3.84% | 2.51% | 0.00% | 0.00% | ||
ROIC |
3.89% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
11.08% | 7.54% | 0.00% | 0.00% | |
Average Days of Receivables |
143.21 | 111.81 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.49) | 0.00 | — | 0.00 | |
Free Cash Flow |
(4.17) | — | — | (0.81) | |
Capital Expenditures |
(3.92) | — | — | (3.72) | |
| Other line items | |||||
Cash ROIC |
(1.76%) | 0.00% | 0.00% | (0.48%) | |
Accounts Receivable Turnover |
3.85 | 4.10 | 0.00 | 0.00 | |
Accounts Payable Turnover |
2.90 | 3.01 | 0.00 | 0.00 | |
Inventory Turnover |
2.31 | 2.35 | 0.00 | 0.00 | |
Average Days of Payables |
130.24 | 129.41 | 0.00 | 0.00 | |
Days of Inventory on Hand |
179.57 | 177.53 | 0.00 | 0.00 | |
Tax Rate |
0.13 | 2.86 | — | — | |
Research and Development Expense of Revenue |
0.15% | 0.13% | — | — | |
Selling, General and Administrative Expense of Revenue |
25.97% | 26.05% | — | — | |
Share Based Compensation of Revenue |
2.28% | 0.00% | — | 0.00% | |
Interest Coverage |
0.95 | 0.00 | — | — | |
Operating CF/Net income |
(0.03) | 0.00 | — | 0.00 | |
Depreciation/Fixed assets |
0.13 | 0.00 | 0.00 | 0.18 | |
Capex/Depreciation |
(1.07) | — | — | (0.69) | |
Revenue per Share |
14.26 | 0.00 | — | — | |
Operating CF per Share |
(0.03) | 0.00 | — | 0.00 | |
Capex per Share |
(0.46) | 0.00 | — | 0.00 | |
Capex to Sales |
0.03 | 0.00 | — | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026